Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the malignancy derived from normal hepatocytes with increasing incidence and extremely poor prognosis worldwide. The only approved first‐line systematic treatment agent for HCC, sorafenib, is capable to effectively improve advanced HCC patients’ survival. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Jimin, Huang, Qichao, Niu, Kunwei, Wang, Bo, Li, Yijie, Dai, Chen, Chen, Zhinan, Tao, Kaishan, Dai, Jingyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247041/
https://www.ncbi.nlm.nih.gov/pubmed/30311444
http://dx.doi.org/10.1002/cam4.1826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247041/
https://www.ncbi.nlm.nih.gov/pubmed/30311444
http://dx.doi.org/10.1002/cam4.1826

Ejemplares similares